Anna Turetsky
General Partner, PxB Fund at OUP (Osage University Partners)
About
Anna Turetsky joined OUP in 2025 as General Partner of the $50M PxB Fund (Penn-BioNTech Innovative Therapeutics Seed Fund), focusing exclusively on life science companies emerging from University of Pennsylvania technologies. She previously launched and led the venture investing arm of the Mark Foundation for Cancer Research and began her career at Lightstone Ventures. She holds a Ph.D. in Biophysics from Harvard University and a B.A. in Biochemistry from the University of Pennsylvania.
Invests in
Biotech
Investments
Board seats
Verseau Therapeutics
Investor
Accent TherapeuticsC2i GenomicsHyku BiosciencesImmunitas TherapeuticsInterius BioTherapeuticsVicinitas Therapeutics
As listed on the firm's website.
Colleagues at OUP (Osage University Partners)
Ajay Rayasam
Principal at OUP (Osage University Partners)
Allen Chen
Principal at OUP (Osage University Partners)
Beth Grafstrom
Senior Vice President at OUP (Osage University Partners)
Bill Harrington
Managing Partner at OUP (Osage University Partners)
Britt Kennett
Senior Executive Assistant at OUP (Osage University Partners)
Brittany de Kouchkovsky
Director, University Relations at OUP (Osage University Partners)
Chris Nawalinski
Fund Accountant at OUP (Osage University Partners)
Claudia Dunnous
Chief Financial Officer at OUP (Osage University Partners)